

INTERNATIONAL SEARCH REPORT

International Application No

T/GB2004/002945

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D217/04 C07D209/44 C07D403/06 C07D223/16 A61K31/472
 A61K31/4035 A61K31/55 A61P25/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WALKER K M ET AL: "THE VR1 ANTAGONIST CAPSAZEPINE REVERSES MECHANICAL HYPERALGESIA IN MODELS OF INFLAMMATORY AND NEUROPATHIC PAIN" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 304, no. 1, January 2003 (2003-01), pages 56-62, XP008025155 ISSN: 0022-3565 page 56, left-hand column, line 1 - page 57, column 7, line 14; figures 1-4	1-22
X	US 5 767 129 A (YUEN PO-WAI) 16 June 1998 (1998-06-16) column 1, line 65 - column 4, line 14; examples 5,10,11	1-22
	----- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

7 October 2004

Date of mailing of the international search report

21/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Usueli, A

INTERNATIONAL SEARCH REPORT

International Application No

T/GB2004/002945

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/051838 A (WELLER THOMAS ; CLOZEL MARTINE (CH); FISCHLI WALTER (CH); ACTELION PHA) 4 July 2002 (2002-07-04) page 1, line 21 - page 2, line 22; claim 1; example 1 -----	1-22
A	WO 03/037890 A (GROSS MICHAEL FRANCIS ; JOHNSON MATTHEW SCOTT (US); ICAGEN INC (US); A) 8 May 2003 (2003-05-08) page 3, line 16 - page 6, line 15 -----	1-22
P,X	WO 03/055848 A (BAYER AG ; TAKESHITA KEISUKE (JP); KOKUBO TOSHIO (JP); MARUMO MAKIKO ()) 10 July 2003 (2003-07-10) page 5, line 20 - page 8, line 9; examples 78,84,85 -----	1-22
A	WALPOLE C S J ET AL: "The discovery of Capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin" JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, 1994, pages 1942-1954, XP002299747 the whole document -----	1-22
X	DATABASE CROSSFIRE BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002299748 Database accession no. BRN:9011654 abstract & J. HETEROCYCL. CHEM., vol. 38, no. 2, 2001, pages 535-538, -----	16
X	DATABASE CROSSFIRE BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002299749 Database accession no. BRN: 13984 abstract & J. AMER. CHEM. SOC., vol. 78, 1956, pages 2439-2445, -----	16
X	DATABASE CROSSFIRE BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE;; XP002299750 Database accession no. BRN:1461685 abstract & CHEM. PHARM. BULL., vol. 23, 1975, pages 1917-1927, -----	16
	----- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

T/GB2004/002945

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p> DATABASE CROSSFIRE BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002299751 Database accession no. BRN:523038 abstract & CHEM. PHARM. BULL., vol. 8, 1960, pages 427-435, ----- </p>	16

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2004/002945

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 22 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members


International Application No

T/GB2004/002945

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5767129	A	16-06-1998	US 5932573 A	03-08-1999
WO 02051838	A	04-07-2002	WO 02051232 A2	04-07-2002
			BR 0116505 A	03-02-2004
			CA 2431982 A1	04-07-2002
			CN 1481380 T	10-03-2004
			WO 02051838 A1	04-07-2002
			EP 1347967 A1	01-10-2003
			JP 2004516324 T	03-06-2004
			NO 20032905 A	24-06-2003
			US 2004058912 A1	25-03-2004
WO 03037890	A	08-05-2003	CA 2465328 A1	08-05-2003
			EP 1451173 A2	01-09-2004
			WO 03037890 A2	08-05-2003
			US 2003171360 A1	11-09-2003
WO 03055848	A	10-07-2003	JP 2003192659 A	09-07-2003
			JP 2003192660 A	09-07-2003
			CA 2469967 A1	10-07-2003
			WO 03055848 A2	10-07-2003
			EP 1461311 A2	29-09-2004

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

Compounds of the formula (I), and pharmaceutically acceptable salts thereof, are found to be antagonists of SNS sodium channels. They are therefore useful as analgesic and neuroprotective agents



wherein:

- X is -N- or -CH-;
- n is from 0 to 3;